Verici DX reported continued progress in the commercial adoption of its kidney transplant diagnostic tests, with higher revenues, increased orders and a shorter sales cycle.
The company said the time required to introduce its Tutivia test at new transplant centres had fallen from around six months to three months. It also reported wider use within existing centres, with several new customers moving quickly towards repeat testing by multiple clinicians.
Verici DX had 36 ordering centres, representing around 20% of its target centres in the US. Revenue from Tutivia increased from $1.1 million to $1.8 million, supported by 825 completed tests. The company reported a gross margin of 72% and an average expected reimbursement of approximately $2,300 per test.
Orders during the first three quarters were around 52% higher year on year, with the company expecting full-year order growth of between 80% and 85%.
Verici DX is targeting cash flow break-even by the end of 2027. It said its recent £8.75 million fundraising had strengthened its financial position and provided funding to support the business towards that target. Further sales recruitment is planned to increase commercial coverage across the US.
The company is also preparing to expand its product portfolio, with a new test expected to launch by the end of 2026. This is intended to complement its existing offering and create further opportunities for revenue growth.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.









































